The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2

M. E. Gore, E. Galligioni, C. W. Keen, R. Sorio, E. M. Loriaux, H. C. Grobben, C. R. Franks

Research output: Contribution to journalArticle

Abstract

Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.

Original languageEnglish
Pages (from-to)329-333
Number of pages5
JournalEuropean Journal of Cancer
Volume30
Issue number3
DOIs
Publication statusPublished - 1994

Keywords

  • interleukin-2
  • renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2'. Together they form a unique fingerprint.

  • Cite this